In which patients would you recommend extending adjuvant AI-based therapy beyond 5 years?

Several keenly awaited trials were presented or published last year. The MA17R looked at extending AI for 5 more years after nearly 10 years of anti-estrogen therapy (5 of which was with an AI). It showed a significant benefit in preventing contra-lateral breast cancers. These are patients who toler...

Genomic assays may be helpful and it is being used in lot of institutions.

Recent SABCS abstract comparing various platforms from TransATAC came up with some interesting findings .( Retrospective analysis)

http://cancerres.aacrjournals.org/content/77/4_Supplement/S6-05

To summarise ( from http://b...